Medline ® Abstract for Reference 13
of 'Hypertriglyceridemia'
13
TI
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.
AU
Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D
SO
J Am Coll Cardiol. 2014 Dec;64(23):2525-40.
Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This "omic" approach recently resulted in new targets for reducing CVD events.
AD
Mount Sinai Heart, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.
PMID